BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.76, $0.02 better than the analyst estimate of $0.74. Revenue for the quarter came in at $766 million versus the consensus estimate of $755.94 million.

GUIDANCE:

BioMarin Pharma sees FY2026 EPS of $4.85-$5.05, versus the consensus of $4.64. BioMarin Pharma sees FY2026 revenue of $3.83-3.93 million, versus the consensus of $3.83 million.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• SpaceX (SPCX) reaches new intraday/all-time highs
• Leerink highlights drug demand rebound after Memorial Day